Trevena names new board member
In January 2009, Dr Ruffolo joined scientific advisory board of Trevena. In addition to that role, Dr Ruffolo has now agreed to become a member of the company’s
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.